Transcriptomic Effects of Peptide Drug Selank during Early Experimental Cerebral Ischemia in Rats

Study findings

At 4.5 hours after arterial occlusion, Selank was associated with 118 differentially expressed genes; 99 were downregulated. Several ischemia-associated immune-expression changes were partly reversed.

Population and setting

Three groups of five rats; RNA sequencing used three animals per group

Evidence type

Animal / experimental

Source language

English

Title source

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

Study limitations

• Early molecular endpoints do not establish functional recovery or human stroke benefit.
• Small RNA-sequencing groups; related program datasets must be checked before treating reports as independent replication.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Review depth: Full-text methods and results check

Source access and review scope

Publisher full-text methods and results checked; no independent reanalysis.

Recorded source-check date: 2026-10-11. This date does not imply a completed systematic review.

Open original source or index record ↗

DOI: 10.1134/S002689332670007X

Citation and original source

Original source: I. B. Filippenkov, Ya. Yu. Shpetko, V. V. Stavchansky, A. E. Denisova, L. V. Gubsky, L. A. Andreeva, N. F. Myasoedov, S. A. Limborska, L. V. Dergunova. Transcriptomic Effects of Peptide Drug Selank during Early Experimental Cerebral Ischemia in Rats Molecular Biology. 2026;60:530–542. 2026.

Molekul research summary: https://molekul.io/research/selank-stroke-transcriptome-2026. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles